Skip to main content
Welcome to Deloitte
If we have selected the wrong experience for you, please change it above.

Built for the long game

Global ambition, made in Auckland


Charlie Xie was never looking for a shortcut to growth. At Unipharm Healthy Manufacturing, progress has come from making long-term commitments and backing them even when the outlook is uncertain.

Unipharm’s manufacturing roots date back to 1979, when its first factory was established. In 2016, a new team led by Charlie acquired the business and built on that legacy. Today, Unipharm operates five manufacturing sites in Auckland and is one of New Zealand’s leading contract development and manufacturing organisations (CDMOs) for dietary supplements.

Unipharm operates behind brands found on shelves and in medicine cabinets around the world. It researches, develops and manufactures dietary supplements and health products, across formats including capsules, tablets, powders, liquids, drops, and sprays. Its customers can arrive with an early formulation and work with the company through every stage, from development to large-scale production.

It is technical work requiring the highest standards of quality and rigorous testing. It is also work built on trust. A brand may carry the name on the packaging, but Unipharm is responsible for what goes inside.

The original vision for the business was straightforward: do what you know and do it well. Over the past five years, investment in new factories and additional capacity has become one of Unipharm’s most important growth drivers. Those commitments carry significant risk. A global economic downturn or changes in New Zealand’s international trading environment can put an expanding business under pressure at any moment. Unipharm chooses to invest anyway.

“We believe in the long-term prospects of the health products sector and want to strengthen Unipharm’s ability to serve international markets,” Charlie says.

That investment extends beyond the factory floor. Unipharm established the New Zealand Food Research Lab to strengthen its research, formulation, and product-development capability. The lab undertakes early-stage work on manufacturing processes, formulations, and patent applications, while keeping pace with emerging technologies and ideas from around the world. The lab has built a portfolio of around 130 patents worldwide, primarily focused on manufacturing processes.

Its researchers then work with Unipharm’s sales team and customers to connect that knowledge with market demand and turn it into products. Unipharm does not want to be a manufacturer that simply receives an order and runs a production line. Its R&D capability allows it to become involved earlier, helping customers develop the products that will eventually move through those lines.

Then comes the challenge of making more without allowing standards to slip.

“Quality starts with people,” Charlie says. As Unipharm expands its factories, it invests in advanced equipment and manufacturing practices. But machinery is only part of the equation. Experienced employees mentor new colleagues, passing on the knowledge that keeps production standards consistent as capacity grows.

That combination supports something less visible but equally important: the confidence of Unipharm’s customers. Charlie believes successful partnerships in the health products industry require common values and a shared commitment to quality.

“Leading brands need leading manufacturing partners. For Unipharm to grow sustainably, we must continue working towards becoming a first-class manufacturer,” he says.

Beyond Unipharm’s own expansion, Charlie sees a wider opportunity for New Zealand manufacturers. Changes in global trade relationships are reshaping supply chains and redirecting established flows of goods. If local businesses can capture those opportunities, he believes more New Zealand companies could reach international scale. Stable trading relationships will be important to that future.

Innovation will open new possibilities along the way. But when asked which matters more, innovation or execution, Charlie chooses execution.

“Consistent, sustained execution is the foundation of steady business development,” he says.

That is Unipharm’s growth story: not one decisive leap, but the cumulative result of continuing to invest, improve, and deliver.

Deloitte Fast 50: Tuned into the future

Entries for the 2026 programme are now closed. Register to stay informed when the Deloitte Fast 50 programme opens for 2027. 

Did you find this useful?

Thanks for your feedback